Unfolding the role of protein misfolding in neurodegenerative diseases
The DOI matches its Crossref record; 152 of the 154 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neurodegenerative diseases, such as AD and DLB, are often characterized as diseases of protein aggregation (30–33).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [30]
In the citing paper
“Importantly, most of these age-related primary neurodegenerative diseases involve disorders of protein processing and aggregation.”
From Glymphatic failure as a final common pathway to dementia (2020) · cites this paper as [59]
In the citing paper
“The hallmark feature of these proteinopathies are the fibrillary aggregates of misfolded or hyperphosphorylated proteins (59).”
From Glymphatic failure as a final common pathway to dementia (2020) · cites this paper as [59]
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundMACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundRosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundGlenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
Background
Cited by
Items 101–200 of 1,001
Low Micromolar Zinc Accelerates the Fibrillization of Human Tau via Bridging of Cys-291 and Cys-322
Mo, Z.-Y., Zhu, Y.-Z., Zhu, H.-L., Fan, J.-B., Chen, J., & Liang, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.058883 · Cited by 188
Amyloidogenesis of Natively Unfolded Proteins
Uversky, V. (2008) · Current Alzheimer Research · doi:10.2174/156720508784533312 · Cited by 188
“nuclear protein of ~800 residues [273–275].”
El-Agnaf, O. M. A., Paleologou, K. E., Greer, B., Abogrein, A. M., King, J. E., Salem, S. A., Fullwood, N. J., Benson, F. E., Hewitt, R., Ford, K. J., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-1346fje · Cited by 187
“To investigate the inhibition specificity of the ASI peptides, we tested their effects on the aggregation of another amyloid protein, namely β-amyloid (Aβ), which is a 39- to 42-residue peptide that plays a central role in the development of AD (reviewed by Soto (11)).”
BackgroundMethodInfluentialSQSTM1/p62: a potential target for neurodegenerative disease
Ma, S., Attarwala, I. Y., & Xie, X.-Q. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00516 · Cited by 185
Apostolidou, M., Jayasinghe, S. A., & Langen, R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801383200 · Cited by 183
Lee, J. H., Won, S. M., Suh, J., Son, S. J., Moon, G. J., Park, U.-J., & Gwag, B. J. (2010) · Experimental and Molecular Medicine · doi:10.3858/emm.2010.42.5.040 · Cited by 183
“…and neuronal death progressively evolving in AD and other neurodegenerative diseases including Parkinson's disease and amyotrophic lateral sclerosis (Bence et al., 2001; Forloni et al., 2002; Ryu et al., 2002; Soto, 2003; Paschen and Mengesdorf, 2005; Kikuchi et al., 2006; Kanekura et al., 2009 ).”
BackgroundThe biochemistry of neuronal necrosis: rogue biology?
Syntichaki, P., & Tavernarakis, N. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1174 · Cited by 183
“Genetic studies associate several neurodegeneration disorders with mutations in genes that encode the proteins that are found in aggregates, which indicates that protein aggregation is causative rather than a symptom of cell deat”
BackgroundThe intricate mechanisms of neurodegeneration in prion diseases
Soto, C., & Satani, N. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.001 · Cited by 181
“oligomers are directly toxic to neurons in culture [11].”
BackgroundInfluentialSelf-citationAmyloid cascade in Alzheimer's disease: Recent advances in medicinal chemistry
Mohamed, T., Shakeri, A., & Rao, P. P. N. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.049 · Cited by 180
Ito, D., Walker, J. R., Thompson, C. S., Moroz, I., Lin, W., Veselits, M. L., Hakim, A. M., Fienberg, A. A., & Thinakaran, G. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9456-9469.2004 · Cited by 181
“It is becoming increasingly clear that the balance between the survival and cell death responses of the UPR is crucial to maintaining normalcy under certain physiological and pathological settings, including acute and chronic brain diseases (11, 49, 57).”
BackgroundProtein aggregation and neurodegenerative diseases: From theory to therapy
Kumar, V., Sami, N., Kashav, T., Islam, A., Ahmad, F., & Hassan, M. I. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.07.054 · Cited by 174
Mercado, G., Castillo, V., Soto, P., López, N., Axten, J. M., Sardi, S. P., Hoozemans, J. J. M., & Hetz, C. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.01.004 · Cited by 179
“amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Prionrelated disorders (PrDs), Huntington's disease among others (Bertram and Tanzi, 2005; Soto, 2003).”
BackgroundInhibition of protein misfolding and aggregation by natural phenolic compounds
Dhouafli, Z., Cuanalo-Contreras, K., Hayouni, E. A., Mays, C. E., Soto, C., & Moreno-Gonzalez, I. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2872-2 · Cited by 170
Self-citationChemistry in Living Cells: Detection of Active Proteasomes by a Two‐Step Labeling Strategy
Ovaa, H., van Swieten, P. F., Kessler, B. M., Leeuwenburgh, M. A., Fiebiger, E., van den Nieuwendijk, A. M. C. H., Galardy, P. J., van der Marel, G. A., Ploegh, H. L., & Overkleeft, H. S. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200351314 · Cited by 173
Heat shock proteins as potential targets for protective strategies in neurodegeneration
Kampinga, H. H., & Bergink, S. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00099-5 · Cited by 172
The prion strain phenomenon: Molecular basis and unprecedented features
Morales, R., Abid, K., & Soto, C. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.12.006 · Cited by 171
“006 observed in Alzheimer's, Parkinson's diseases and many other protein misfolding disorders [4].”
BackgroundSelf-citationGandhi, J., Antonelli, A. C., Afridi, A., Vatsia, S., Joshi, G., Romanov, V., Murray, I. V. J., & Khan, S. A. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0035 · Cited by 164
Residues 17–20 and 30–35 of beta‐amyloid play critical roles in aggregation
Liu, R., McAllister, C., Lyubchenko, Y., & Sierks, M. R. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.10859 · Cited by 167
“There are at least two intermediates in the pathway from monomer to fibrils: soluble, low-molecular weight oligomers (dimers to decamers) and protofibrils (short flexible, rod-like structures; Soto, 2003).”
BackgroundInfluentialSmall molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs
Arakawa, T., Ejima, D., Kita, Y., & Tsumoto, K. (2006) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2006.08.012 · Cited by 166
The Unfolded Protein Response and the Role of Protein Disulfide Isomerase in Neurodegeneration
Perri, E. R., Thomas, C. J., Parakh, S., Spencer, D. M., & Atkin, J. D. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00080 · Cited by 164
The size-effect of gold nanoparticles and nanoclusters in the inhibition of amyloid-β fibrillation
Gao, G., Zhang, M., Gong, D., Chen, R., Hu, X., & Sun, T. (2017) · Nanoscale · doi:10.1039/c7nr00699c · Cited by 164
Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Estrada, L., & Soto, C. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607779318262 · Cited by 162
Self-citationYan, L., Velkova, A., Tatarek‐Nossol, M., Andreetto, E., & Kapurniotu, A. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200604056 · Cited by 161
Mutter, M., Chandravarkar, A., Boyat, C., Lopez, J., Dos Santos, S., Mandal, B., Mimna, R., Murat, K., Patiny, L., Saucède, L., et al. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200454045 · Cited by 162
Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols
Camilleri, A., Zarb, C., Caruana, M., Ostermeier, U., Ghio, S., Högen, T., Schmidt, F., Giese, A., & Vassallo, N. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.026 · Cited by 163
“The hallmark in both pathologies is the accumulation and aggregation of misfolded proteins [1].”
Noorwez, S. M., Malhotra, R., McDowell, J. H., Smith, K. A., Krebs, M. P., & Kaushal, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312101200 · Cited by 159
TIA1 oxidation inhibits stress granule assembly and sensitizes cells to stress-induced apoptosis
Arimoto-Matsuzaki, K., Saito, H., & Takekawa, M. (2016) · Nature Communications · doi:10.1038/ncomms10252 · Cited by 158
“Indeed, augmentation of SG formation in U2OS cells by expression of GFP-G3BP, an efficient inducer of SG formation5, suppressed thapsigargininduced, ER stress-mediated apoptosis, as assessed by Annexin V staining (Supplementary Fig.”
BackgroundKoszła, O., & Sołek, P. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01791-8 · Cited by 178
“In the context of therapeutic synergy, particularly through the application of drugs with diverse mechanisms of action, represents a prospective trajectory in the therapeutic landscape for individuals afflicted by neuro-degenerative diseases [57].”
BackgroundEndocytic membrane trafficking and neurodegenerative disease
Schreij, A. M. A., Fon, E. A., & McPherson, P. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2105-x · Cited by 162
Corbett, G. T., Wang, Z., Hong, W., Colom-Cadena, M., Rose, J., Liao, M., Asfaw, A., Hall, T. C., Ding, L., DeSousa, A., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-019-02114-9 · Cited by 157
Land, W. G. (2015) · Sultan Qaboos University Medical Journal · doi:10.18295/2075-0528.1676 · Cited by 154
Jayasinghe, S. A., & Langen, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406853200 · Cited by 153
Rodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
Gennarino, V. A., Singh, R. K., White, J. J., De Maio, A., Han, K., Kim, J.-Y., Jafar-Nejad, P., di Ronza, A., Kang, H., Sayegh, L. S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.02.012 · Cited by 155
“Alzheimer disease (AD), Parkinson disease (PD), amyo- trophic lateral sclerosis (ALS), and polyglutamine diseases such as Huntington disease all fall into this category (Ross and Poirier, 2004; Soto, 2003).”
BackgroundProtein aggregation can inhibit clathrin-mediated endocytosis by chaperone competition
Yu, A., Shibata, Y., Shah, B., Calamini, B., Lo, D. C., & Morimoto, R. I. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321811111 · Cited by 151
“Although the underlying disease origins may be genetically inherited or manifest sporadically, as exemplified by Huntington disease and ALS, respectively, the pathologies of these maladies all share the common molecular occurrence of protein aggregation (6).”
BackgroundHuntington’s Disease and Mitochondria
Farshbaf, M. J., & Ghaedi, K. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9766-1 · Cited by 160
“…make inclusion and aggregate forms in the nucleus and cytoplasm (DiFiglia et al. 1997). βSheet structures are the most abundant components of the amyloid fibers in the mHtt. Insolubility and toxicity of the aggregate protein, mHtt, in the HD are the main reason of the neuronal death (Soto 2003).”
Inhibition of Amyloid Fibril Formation by Peptide Analogues Modified with α‐Aminoisobutyric Acid
Gilead, S., & Gazit, E. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200353565 · Cited by 147
Microglial priming of antigen presentation and adaptive stimulation in Alzheimer’s disease
Das, R., & Chinnathambi, S. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03132-2 · Cited by 147
Targeting autophagy in neurodegenerative diseases
Vidal, R. L., Matus, S., Bargsted, L., & Hetz, C. A. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.09.002 · Cited by 155
Jones, E. M., Dubey, M., Camp, P. J., Vernon, B. C., Biernat, J., Mandelkow, E., Majewski, J., & Chi, E. Y. (2012) · Biochemistry · doi:10.1021/bi201857v · Cited by 143
“Alzheimer's disease (AD) is a neurodegenerative disease characterized by neurofibrillary tangles (NFTs) and amyloid plaques found in the brains of affected patients (1, 2).”
BackgroundProtein misfolding and aggregation: Mechanism, factors and detection
Chaturvedi, S. K., Siddiqi, M. K., Alam, P., & Khan, R. H. (2016) · Process Biochemistry · doi:10.1016/j.procbio.2016.05.015 · Cited by 154
Mapping interactions with the chaperone network reveals factors that protect against tau aggregation
Mok, S.-A., Condello, C., Freilich, R., Gillies, A., Arhar, T., Oroz, J., Kadavath, H., Julien, O., Assimon, V. A., Rauch, J. N., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0057-1 · Cited by 149
Chi, E. Y., Ege, C., Winans, A., Majewski, J. P., Wu, G., Kjær, K., & Lee, K. Y. C. (2008) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21887 · Cited by 150
“For the DPPG monolayer, the coherence length of the 2D lipid crystallites is reduced from 600 Å for the hexagonal phase of the pure lipid to 110 and 250 Å in the two crystallographic directions [(1,0), (0,1)] and (21,1), respectively, with the addition of Ab.”
BackgroundProtective Mechanisms of Flavonoids in Parkinson’s Disease
Magalingam, K. B., Radhakrishnan, A. K., & Haleagrahara, N. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/314560 · Cited by 139
“Apart from that, the neuroprotective effects of polyphenols in protecting neuronal cells were further demonstrated in animal studies using naringin [36].”
DNAJ Proteins in neurodegeneration: essential and protective factors
Zarouchlioti, C., Parfitt, D. A., Li, W., Gittings, L. M., & Cheetham, M. E. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0534 · Cited by 149
“Intracellular or extracellular proteinaceous inclusions in specific brain regions are a pathological hallmark of many neurodegenerative diseases [1].”
BackgroundBiological and medical physics, biomedical engineering
Herman, I. P. (2014) · Cited by 136
Integrating the stress response: lessons for neurodegenerative diseases from C. elegans
Prahlad, V., & Morimoto, R. I. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.11.002 · Cited by 133
“elegans muscle and neuronal tissues [82–84] recapitulates aspects of HD, including formation of Q-length-dependent intracellular aggregates that cause toxicity [81].”
Araki, K., Yagi, N., Aoyama, K., Choong, C., Hayakawa, H., Fujimura, H., Nagai, Y., Goto, Y., & Mochizuki, H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906124116 · Cited by 141
Amyloid Formation Modulates the Biological Activity of a Bacterial Protein
Bieler, S., Estrada, L., Lagos, R., Baeza, M., Castilla, J., & Soto, C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502031200 · Cited by 132
Self-citationThe Role of Microglia in Synaptic Stripping and Synaptic Degeneration: A Revised Perspective
Perry, V. H., & O’Connor, V. (2010) · ASN Neuro · doi:10.1042/an20100024 · Cited by 132
“There are important diseases of the CNS that are associated with the accumulation of misfolded proteins either extracellularly, such as Alzheimer’s disease and prion diseases, or intracellularly, such as Parkinson’s disease and ALS (amyotrophic lateral sclerosis) (Soto, 2003).”
BackgroundRole of Protein Misfolding and Proteostasis Deficiency in Protein Misfolding Diseases and Aging
Cuanalo-Contreras, K., Mukherjee, A., & Soto, C. (2013) · International Journal of Cell Biology · doi:10.1155/2013/638083 · Cited by 130
“Several pathological and clinical characteristics of PMDs have been observed in transgenic models in which protein aggregates were produced.”
BackgroundInfluentialSelf-citationZaman, M., Khan, A. N., Wahiduzzaman, Zakariya, S. M., & Khan, R. H. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.05.109 · Cited by 138
Polyphenols Beyond Barriers: A Glimpse into the Brain
Figueira, I., Menezes, R., Macedo, D., Costa, I., & dos Santos, C. N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666161026151545 · Cited by 128
“These diseases can arise from hereditary or sporadic conditions, having a complex pathogenesis that triggers atrophy of central or peripheral structures of the nervous system [2].”
Determination of Polypeptide Conformation with Nanoscale Resolution in Water
Ramer, G., Ruggeri, F. S., Levin, A., Knowles, T. P. J., & Centrone, A. (2018) · ACS Nano · doi:10.1021/acsnano.8b01425 · Cited by 135
Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders
Njomen, E., & Tepe, J. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00101 · Cited by 136
Gallegos, S., Pacheco, C. R., Peters, C., Opazo, C., & Aguayo, L. G. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00059 · Cited by 150
“REVIEW ARTICLE published: 09 March 2015 doi: 10.3389/fnins.2015.00059 Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson’s disease”
BackgroundInfluentialCrucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases
Choi, M. L., & Gandhi, S. (2018) · The FEBS Journal · doi:10.1111/febs.14587 · Cited by 127
Tracking Fiber Formation in Human Islet Amyloid Polypeptide with Automated 2D-IR Spectroscopy
Strasfeld, D. B., Ling, Y. L., Shim, S., & Zanni, M. T. (2008) · Journal of the American Chemical Society · doi:10.1021/ja801483n · Cited by 128
General aspects of neurodegeneration
Jellinger, K. A. (2003) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-0643-3_7 · Cited by 126
Regulated cell death: discovery, features and implications for neurodegenerative diseases
Cui, J., Zhao, S., Li, Y., Zhang, D., Wang, B., Xie, J., & Wang, J. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00799-8 · Cited by 138
Protein misfolding in neurodegenerative diseases
Agorogiannis, E. I., Agorogiannis, G. I., Papadimitriou, A., & Hadjigeorgiou, G. M. (2004) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2004.00558.x · Cited by 126
Neurotrophic Natural Products: Chemistry and Biology
Xu, J., Lacoske, M. H., & Theodorakis, E. A. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201302268 · Cited by 131
Current Understanding of Autophagy in Pregnancy
Nakashima, A., Tsuda, S., Kusabiraki, T., Aoki, A., Ushijima, A., Shima, T., Cheng, S., Sharma, S., & Saito, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092342 · Cited by 144
“Protein aggregation caused by autophagy suppression has been reported in several neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease [56,57].”
BackgroundPost-translational modifications: Regulators of neurodegenerative proteinopathies
Gupta, R. V., Sahu, M., Srivastava, D., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101336 · Cited by 133
Fluorescent probes for proteolysis: Tools for drug discovery
Neefjes, J., & Dantuma, N. P. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1282 · Cited by 136
“Because misfolded proteins tend to aggregate, the rapid recognition and degradation of such aberrant proteins is crucial for the survival of the cell 5, 6 .”
BackgroundSantos, S. D., Chandravarkar, A., Mandal, B., Mimna, R., Murat, K., Saucède, L., Tella, P., Tuchscherer, G., & Mutter, M. (2005) · Journal of the American Chemical Society · doi:10.1021/ja052083v · Cited by 123
Jia, S., Zheng, L., Gao, Z., An, J., Wu, X., Li, X., Dai, X., Zheng, Q., & Sun, Y. (2015) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.11.011 · Cited by 128
Fecal transmission of AA amyloidosis in the cheetah contributes to high incidence of disease
Zhang, B., Une, Y., Fu, X., Yan, J., Ge, F., Yao, J., Sawashita, J., Mori, M., Tomozawa, H., Kametani, F., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800367105 · Cited by 122
Chemical Chaperones: Mechanisms of Action and Potential Use
Papp, E., & Csermely, P. (2005) · Springer eBooks · doi:10.1007/3-540-29717-0_16 · Cited by 124
Therapeutic Effect of Berberine on Huntington’s Disease Transgenic Mouse Model
Jiang, W., Wei, W., Gaertig, M. A., Li, S., & Li, X.-J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134142 · Cited by 124
“It is also known that the accumulation of toxic forms of peptides and misfolded proteins can lead to a variety of pathological events such as inflammation and altered cellular signaling [50, 51], which could explain the broad protective effects of BBR on a variety of pathological events.”
BackgroundQing, G., Zhao, S., Xiong, Y., Lv, Z., Jiang, F., Liu, Y., Chen, H., Zhang, M., & Sun, T. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5049626 · Cited by 122
Masino, L., Nicastro, G., Menon, R. P., Piaz, F. D., Calder, L. J., & Pastore, A. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.09.065 · Cited by 120
Protein aggregation, metals and oxidative stress in neurodegenerative diseases
Tabner, B. J., El-Agnaf, O. M. A., German, M. J., Fullwood, N. J., & Allsop, D. (2005) · Biochemical Society Transactions · doi:10.1042/bst0331082 · Cited by 117
Phase Separation, Transition, and Autophagic Degradation of Proteins in Development and Pathogenesis
Wang, Z., & Zhang, H. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.008 · Cited by 117
Conformational diseases: Looking into the eyes
Surguchev, A. A., & Surguchov, A. P. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.09.015 · Cited by 127
A Genetic Screening Strategy Identifies Novel Regulators of the Proteostasis Network
Silva, M. C., Fox, S., Beam, M., Thakkar, H., Amaral, M. D., & Morimoto, R. I. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002438 · Cited by 119
“These are common and prominent features in Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), polyglutamine disorders such as Huntington’s disease (HD), muscular dystrophies, metabolic disorders, and certain cancers [1–5].”
BackgroundGreen Tea Extracts EGCG and EGC Display Distinct Mechanisms in Disrupting Aβ42 Protofibril
Zhan, C., Chen, Y., Tang, Y., & Wei, G. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00277 · Cited by 115
The unfolded protein response in Alzheimer’s disease
Cornejo, V. H., & Hetz, C. A. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-013-0373-9 · Cited by 129
“now classified as protein misfolding disorders (PMDs) [2].”
BackgroundOligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases
Forloni, G., Artuso, V., La Vitola, P., & Balducci, C. (2016) · Movement Disorders · doi:10.1002/mds.26624 · Cited by 113
“neurodegeneration in AD.(9) The concept originally arose from studies showing that the relation between amyloid fibrils and neurotoxicity has progressively lost ground.”
BackgroundInfluentialPharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases
Tao, Y.-X., & Conn, P. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00029.2016 · Cited by 115
“are directed to the following classical as well as current review articles on this topic for further information, with some of these articles focused on loss-of-function mutations and others focused on gain-of-function mutations (14, 15, 41, 56, 64, 65, 70, 129, 142, 212, 279, 312, 338, 344, 371, 392).”
BackgroundGonçalves, P. B., Sodero, A. C. R., & Cordeiro, Y. (2021) · Biomolecules · doi:10.3390/biom11050767 · Cited by 120
“Finally, in view of multiple lines of evidence that support protein misfolding as a common cause and pathological mechanism in NDs, it has been suggested that a common therapy for these incurable disorders might be possible [24].”
BackgroundInfluentialKang, E., Kwon, I., Koo, J., Kim, E.-J., Kim, C., Lee, J., Yang, C.-H., Lee, Y.-I., Cho, I., & Cho, J. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0884-9 · Cited by 131
“The pathological activation of UPR due to Ab-induced ER stress also becomes prominent cause of neuronal cell death in the brain of AD mice and humans [22, 41–48].”
Convertino, M., Das, J., & Dokholyan, N. V. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00195 · Cited by 105
Amyloid structure – one but not the same: the many levels of fibrillar polymorphism
Pedersen, J. S., Andersen, C. B., & Otzen, D. E. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07888.x · Cited by 115
Protein misfolding and amyloid nucleation through liquid–liquid phase separation
Mukherjee, S., Poudyal, M., Dave, K., Kadu, P., & Maji, S. K. (2024) · Chemical Society Reviews · doi:10.1039/d3cs01065a · Cited by 123
Liu, R., Yuan, B., Emadi, S., Zameer, A., Schulz, P., McAllister, C., Lyubchenko, Y., Goud, G., & Sierks, M. R. (2004) · Biochemistry · doi:10.1021/bi049933o · Cited by 113
Secondary Structure Dependent Self‐Assembly of β‐Peptides into Nanosized Fibrils and Membranes
Martinek, T. A., Hetényi, A., Fülöp, L., Mándity, I. M., Tóth, G. K., Dékány, I., & Fülöp, F. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200504158 · Cited by 113
Protein Misfolding and ER Stress in Huntington's Disease
Shacham, T., Sharma, N., & Lederkremer, G. Z. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00020 · Cited by 120
“The aggregation process triggers cellular dysfunction, loss of synaptic connections and is responsible for brain damage or disease (Soto, 2003; Ross and Poirier, 2004; Goedert, 2015; Soto and Pritzkow, 2018).”
BackgroundCrowded Cell-like Environment Accelerates the Nucleation Step of Amyloidogenic Protein Misfolding
Zhou, Z., Fan, J.-B., Zhu, H.-L., Shewmaker, F., Yan, X., Chen, X., Chen, J., Xiao, G.-F., Guo, L., & Liang, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.002832 · Cited by 112
Matsumoto, G., Kim, S., & Morimoto, R. I. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509201200 · Cited by 113
Protein folding alterations in amyotrophic lateral sclerosis
Parakh, S., & Atkin, J. D. (2016) · Brain Research · doi:10.1016/j.brainres.2016.04.010 · Cited by 122
Martinelli, C., Pucci, C., Battaglini, M., Marino, A., & Ciofani, G. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201901589 · Cited by 119
Transgenic Drosophila models of Alzheimer’s disease and tauopathies
Iijima‐Ando, K., & Iijima, K. (2009) · Brain Structure and Function · doi:10.1007/s00429-009-0234-4 · Cited by 128
“Many late-onset neurodegenerative diseases including Alzheimer’s disease (AD), tauopathies, Parkinson’s disease, Huntington’s disease and other polyglutamine diseases, amyotrophic lateral sclerosis (ALS), and prion disease are characterized by accumulation of misfolded proteins (Soto 2003).”
APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia
Liu, C.-C., Murray, M. E., Li, X., Zhao, N., Wang, N., Heckman, M. G., Shue, F., Martens, Y., Li, Y., Raulin, A.-C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc9375 · Cited by 108
Gadad, B. S., Britton, G. B., & Rao, K. S. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110182 · Cited by 108
“PrP contains a large intrinsically disordered N-terminal region followed by a folded C-terminal domain [1, 24, 25].”
InfluentialReversal of amyloid-induced heart disease in desmin-related cardiomyopathy
Sanbe, A., Osinska, H., Villa, C., Gulick, J., Klevitsky, R., Glabe, C. G., Kayed, R., & Robbins, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503324102 · Cited by 107
van Raaij, M. E., Segers‐Nolten, I. M. J., & Subramaniam, V. (2006) · Biophysical Journal · doi:10.1529/biophysj.106.090449 · Cited by 111
Folding Efficiency Is Rate-limiting in Dopamine D4 Receptor Biogenesis
Van Craenenbroeck, K., Clark, S. D., Cox, M. J., Oak, J. N., Liu, F., & Van Tol, H. H. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414043200 · Cited by 107
Andreu, C. I., Woehlbier, U., Torres, M., & Hetz, C. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.07.023 · Cited by 105
“is a hallmark of all these pathologies [2], which are collectively classified as protein misfolding disorders (PMDs) [2].”
BackgroundAndreasen, M., Lorenzen, N., & Otzen, D. E. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.01.018 · Cited by 112
Metadata
- Authors
- Soto, C.
- Corresponding author
- Soto, Claudio
- ORCID
- Soto, Claudio
- Venue
- Nature Reviews Neuroscience
- Published
- 2003-01
- Volume
- 4
- Issue
- 1
- Pages
- 49-60
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2007157911
- Cited by
- 1,506
- References
- 154
- Citations by year
- 2026: 45 · 2025: 70 · 2024: 75 · 2023: 73 · 2022: 95 · 2021: 88 · 2020: 107 · 2019: 80 · 2018: 86 · 2017: 107 · 2016: 92 · 2015: 75 · 2014: 67 · 2013: 45 · 2012: 57
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- protein misfolding, neurodegenerative diseases, protein aggregation, protein accumulation, neuronal apoptosis, common pathogenic mechanisms, therapeutic target
- MeSH terms
- Animals, Brain, Brain Chemistry, Humans, Protein Folding, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.